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SCIENTIFIC EDITORIAL
Cardiogenic shock complicating myocardial 
infarction: a lost cause or reasons for hope?
Choc cardiogénique de l’infarctus du myocarde : 
cause perdue ou raisons d’espérer ?
D. Himbert*
Département de cardiologie, Groupe hospitalier Bichat — Claude-Bernard (AP-HP), Paris.
Cardiogenic shock is still by far the leading cause of morta-
lity during the acute phase of myocardial infarction. There
has only been a very slight fall in its incidence of nearly 6%
in patients hospitalized for infarction. However, its progno-
sis has improved during the last decade following the more
widespread use of emergency revascularization by primary
angioplasty, with a reduction of in-hospital mortality from
60-65% in 1995 to 45-50% today [1]. In particular, patients
surviving the hospital phase may now hope for an excellent
prognosis and good long-term quality of life [2, 3]. This
combination of still unacceptable early mortality and the
prospect of good long-term prognosis for survivors should
therefore encourage “maximalist” management during the
acute phase. In this edition, Samadi et al. show that in-hos-
pital and 6-months mortality remain catastrophic (70 and
78% respectively) in patients aged over 75 years hospitali-
zed for myocardial infarction complicated by cardiogenic
shock, despite optimal revascularization by primary angio-
plasty with intra-aortic balloon counterpulsation [4]. This
result is explainable but disappointing. Explainable, as it
has been clearly shown that cardiogenic shock and age are
by far the 2 most powerful predictors of post-infarction
mortality. Explainable also by the mitigated results obtai-
ned when this strategy was systematically used to manage
elderly subjects in the SHOCK study (SHould we emergently
revascularize Occluded coronary arteries for Cardiogenic
shocK), raising the question of the selection of patients who
may benefit from this procedure in this age range [5].
However, these results are disappointing , as progress in
angioplasty made since the SHOCK study, with the systema-
tic use of stents and the improvement in the anti-thrombo-
tic environment, has raised hopes that revascularization
and its subsequent prognosis would be improved. Disap-
pointing also because of the high-quality multidisciplinary
management that these patients certainly received, in a
reference institution grouping all the essential skills requi-
red to treat serious cardiovascular diseases. These results
should not lead to discouragement, and as pointed out by
the authors in their conclusion, they should persuade us “to
evaluate the respective place of surgical revascularization
and circulatory support”.
In shock after myocardial infarction, the best revascu-
larization strategy has not been clearly determined for
multivessel coronary disease, which was the case for
nearly 90% of the patients in the SHOCK study. In certain
cases, coronary anatomy lends itself better to surgery
than to angioplasty, and angioplasty of arteries not
responsible for the infarct may be hazardous under such
unstable hemodynamic conditions. In the SHOCK study,
despite the more severe clinical and angiographic charac-
teristics (three-vessel or left main trunk disease, diabetes
etc.), the patients treated by surgical revascularization
had an identical survival and quality of life as patients
treated by angioplasty [6]. Recent data of the Society of
Thoracic Surgeons National Cardiac Database indicate an
operative mortality of 20% for surgical revascularization
after infarction complicated by shock , and 33% when
revascularization is associated with heart valve surgery
[7]. Today, emergency bypass surgery is too rarely consi-
dered. If it is used more often in appropriate cases, and
thanks to recent progress (beating-heart techniques, sys-
tematic use of the internal mammary artery, etc.)
contemporary cardiac surgery would permit a substantial
improvement in the prognosis of these patients. The other
promising avenue of investigation is circulatory support.
In theory, temporary left ventricular assist support is the
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ideal way of stopping the ischemia-hypotension-myocar-
dial dysfunction spiral, permit recovery from ventricular
stunning and await the disappearance of neurohormonal
disturbances. This approach is restricted in practice by
the complications of current devices and irreversible ven-
tricular lesions [8]. 
Schematically, circulatory support may be used in 3 dif-
ferent manners..As a bridge to recovery. In this case, percutaneous extra-
corporeal assist devices, such as the ECMO (Extra-Corpo-
real Membrane Oxygenator), TandemHeart™ or Impella™
systems, are used. This approach remains disappointing.
Current data, including 2 randomized TandemHeart vs
intra-aortic balloon pump studies [9, 10], suggest that,
despite the hemodynamic improvement in the mechani-
cal support group, hospital mortality was not decreased
because of the secondary occurrence of multiorgan
failure. .As a bridge to transplantation. In this case, percutaneous
and then surgically implanted assist devices, are used
sequentially (“Bridge to bridge”). In the largest series
reported to date, involving 49 patients, 74% survived
transplantation and 87% of transplant recipients survived
beyond the hospital phase [11]. The Rouen series,
recently published in this journal, also shows the feasibi-
lity of such an approach, with encouraging results [12].
However, the shortage of organs and the large number of
patients who, in this context, are not candidates for
transplantation – in particular elderly subjects – are major
obstacles to its widespread use. .It is therefore possible that the most promising solution
for the future is, for many patients, the implantation of
an indwelling LVAD [12, 13]. In addition to currently
unresolved technical issues, it will then be necessary to
precisely define selection criteria of candidates accor-
ding to strict clinical parameters, irreproachable ethical
rules, within the framework of rigorous economic
constraints. 
A final, inflammatory, peripheral vascular and neurohor-
monal approach should be mentioned. Cardiogenic shock
during myocardial infarction causes a systemic inflamma-
tory response syndrome [SIRS] responsible among other
things for inappropriate peripheral vasodilatation [14]. A
large rise in cytokine levels then rapidly occurs. Tumor
Necrosis Factor-d and interleukin-6 have a myocardial
depressant effect. Complement is also involved in SIRS.
Despite an encouraging phase 2 study , a trial on the inhibi-
tion of complement C5 by pexelizumab did not show an
effect either on the occurrence or mortality of cardiogenic
shock [14]. However the most interesting avenue of
research concerns NO. Serious infarction causes an increase
in the expression of inducible NO synthase, leading to
excessively high NO levels, responsible for vasodilatation,
myocardial depression and interference with the action of
catecholamines. Although the randomized study TRIUMPH
(Tilarginine Acetate Injection in a Randomized Internatio-
nal Study in Unstable MI Patients with Cardiogenic Shock)
was negative [15], this approach has not been abandoned
and other studies will be necessary to definitively confirm
the role of SIRS and inducible NO synthase in the prevention
and treatment of post-infarction cardiogenic shock.
Cardiogenic shock which is responsible for 60% of deaths
during the acute phase of myocardial infarction is still the
main target disorder for therapy to substantially improve
prognosis. During the last decade, an improved use of
resources has made it possible to obtain a definite reduc-
tion in mortality, thanks to primary angioplasty with intra-
aortic balloon pumping. It is therefore necessary to conti-
nue this approach and encourage increasingly invasive
management of serious infarcts. However, the study by
Samadi et al. [4] shows that, even when it is conducted
under the best possible conditions, percutaneous revascula-
rization remains ineffective in many patients, and, in parti-
cular, in elderly subjects. The improvement in the pro-
gnosis of cardiogenic shock therefore requires the
implementation of other revascularization strategies, the
development of circulatory support and the investigation of
new medications. Cardiogenic shock should then no longer
be a lost cause for many patients, but a curable disorder
with a reasonable chance of recovery. There are still there-
fore reasons to hope… though it should always be born in
mind that the best treatment will be always preventive, by
effective and early reperfusion during the acute phase of
infarction.
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